Foreign investors continue to sell Indian shares. November saw outflows of Rs 3,788 crore. This follows significant selling throughout 2025. Experts note improved sentiment but tentative flows. Valuations and earnings clarity are key concerns. Investors await earnings growth to catch up before increasing exposure. Year-end portfolio rebalancing will offer clues.
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt’s shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. The drug, combining cefepime and zidebactam,
June 1, 2026